Sermorelin, CJC-1295 and Ipamorelin: GHRH Analogs Versus a Ghrelin Mimetic
Writing on growth-hormone secretagogues frequently blurs two separate receptor systems together. Sorting the three most studied compounds by mechanism, with sermorelin and CJC-1295 on one side and ipamorelin on the other, makes them much easier to compare.
One pulse, two receptors
Sermorelin and CJC-1295 are GHRH analogs. They bind the GHRH receptor in the anterior pituitary, the same receptor the hypothalamus uses to set off natural GH pulses. Ipamorelin is a ghrelin mimetic and works through a different receptor altogether, GHS-R1a. It amplifies the pulse and suppresses somatostatin, the brake on GH release. Published models find the two mechanisms synergistic.
That synergy is the logic behind pairing. The GHRH analog starts the pulse, and the ghrelin mimetic makes it larger while lifting somatostatin suppression. In rodent and human physiology studies, the combination released more GH than either compound alone at the same doses, which is why one compound from each family is the standard pairing in secretagogue research.
Why short half-lives are useful
GH is released in pulses, and what happens downstream, including IGF-1 induction and receptor sensitivity, depends on that rhythm being kept. For that reason researchers see the short half-lives of GHRH analogs as a design advantage. The long-acting DAC form of CJC-1295 turns the pulses into a continuous elevation, so it asks a deliberately different pharmacological question.
Compound profiles
| Ipamorelin | Sermorelin | CJC-1295 (no DAC) | |
|---|---|---|---|
| What it is | Ghrelin-mimetic pentapeptide | GHRH analog, GRF(1-29) | GRF(1-29) with four substitutions |
| Target | GHS-R1a | GHRH-R | GHRH-R |
| Half-life reported in research | ~2 hours | ~10–20 minutes | ~30 minutes |
| Distinguishing feature | Notably selective; published data show minimal cortisol, prolactin or appetite signal compared with older mimetics such as GHRP-6 | Closely mimics native GHRH | Substitutions resist DPP-4 cleavage, keeping the same pulse shape with longer action |
| Development history | Reached early clinical trials for postoperative ileus, then discontinued | Once an approved pediatric diagnostic and therapeutic (Geref), later withdrawn commercially | Research compound only |
Tesamorelin is the only GHRH analog in this group with current FDA approval (for HIV-associated lipodystrophy), which makes it the obvious positive control.
What the store carries
On the GHRH side: Sermorelin (5mg, 10mg), CJC-1295 (No DAC) (5mg, 10mg), CJC-1295 with DAC (5mg) and Tesamorelin (5mg, 10mg, 20mg). On the ghrelin-mimetic side: Ipamorelin (5mg, 10mg) and GHRP-6 Acetate (5mg, 10mg). Paired: CJC-1295 (No DAC) + Ipamorelin Blend (10mg, 20mg).
Two Freedom Diagnostics Testing reports for LiliPeptide samples on our COAs page touch this group. One is for CJC-1295 + Ipamorelin 10mg, batch 20260701, tested 25 Jul 2026, report Lili2607220458. The page names that sample without saying which CJC-1295 form it contains, so check the PDF before relating it to the blend listing. The other is for Tesamorelin 5mg, batch LIL422026WHT, tested 23 Sep 2026, report LILI2609210552. Each applies only to the sample it identifies. The page has no report for sermorelin, for ipamorelin on its own, for either single CJC-1295 listing, or for GHRP-6.
For research use only. Not for human or veterinary use.
